<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437786</url>
  </required_header>
  <id_info>
    <org_study_id>GT-20</org_study_id>
    <nct_id>NCT02437786</nct_id>
  </id_info>
  <brief_title>Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®</brief_title>
  <acronym>GT-20</acronym>
  <official_title>Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific clinical trial is a part in which ALK- Abelló will directly work to explore
      human immunological mechanisms of SIT (observed after GRAZAX treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main idea of the project was to address the study of some of the most important
      inflammatory diseases (psoriasis, rheumatoid arthritis, lupus, rhinitis/asthma… ) with the
      aim of identifying novel inflammatory markers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in immunological markers (composite) measured in grass allergic subjects during treatment with Grazax®</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with IMP related adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>GRAZAX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRAZAX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRAZAX</intervention_name>
    <description>GRAZAX</description>
    <arm_group_label>GRAZAX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before entering the trial.

          -  Male and female 18-65 years of age.

          -  A clinical history of relevant rhinitis or rhinoconjunctivitis (with/without
             concurrent asthma) to grass pollen of at least one year prior to trial entry.

          -  Documented positive specific IgE against grass pollen (IgE ≥ Class 2) into the 5
             previous years.

          -  Positive Skin Prick Test response (wheal diameter ≥ 3 mm) to Phleum pratense.

          -  Negative pregnancy test for childbearing potential females.

          -  Willing and able to comply with the trial protocol regimen.

        Exclusion Criteria:

          -  Previous treatment by immunotherapy with grass allergen extracts.

          -  A clinical history of symptomatic perennial allergic rhinitis or asthma.

          -  Patients with contraindications for immunotherapy as established by the IT
             subcommittee of the EAACI or in the Summary of Products Characteristics of GRAZAX®.

          -  Positive pregnancy test (in fertile females).

          -  Being immediate family of the investigator or trial staff.

          -  A mental condition rendering the subject unable to understand the nature, scope and
             possible consequences of the trial, and/or evidence of an uncooperative attitude.

          -  Unlikely to be able to complete the trial, for any reason, or likely to move, or
             travel for extended periods of time during the trial period.

          -  Use of an investigational drug within 30 days or 5 half-lives, whichever is longest,
             prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CARLOS BLANCO, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE LA PRINCESA MADRID</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, de Frutos C, Blanco C, Carrera AC, Barber D, Varona R. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol. 2014 Jan;133(1):130-8.e1-2. doi: 10.1016/j.jaci.2013.09.043. Epub 2013 Nov 28.</citation>
    <PMID>24290282</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

